Evidence map›Paper›PMID 35122060›Full record

Trial reportNature cancer2021

Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.

Aparna R Parikh, Annamaria Szabolcs, Jill N Allen, Jeffrey W Clark, Jennifer Y Wo, Michael Raabe, Hannah Thel, David Hoyos, Arnav Mehta, Sanya Arshad and 21 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03104439 (Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable), which is not on this map. Cited by 189 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed, 8 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03104439 phase2active not recruitingnot on this map

Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer

TypeinterventionalSponsorMassachusetts General HospitalRan2017 to 2027Enrolled84ConditionsMicrosatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal CancerArmsNivolumab, Ipilimumab, Radiation Therapy
3 · Its place in the literature

Who cites it

189 citing papers in PubMed, 8 syntheses or guidelines pooled it, 275 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

129 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 3 institutions in 1 country.

Aparna R Parikh *Department of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5245-7841
Annamaria Szabolcs *Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Jill N AllenDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Jeffrey W ClarkDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Jennifer Y WoDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Michael RaabeMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Hannah ThelMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
David HoyosMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Arnav MehtaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Sanya ArshadMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
David J LiebThe Broad Institute, Cambridge, MA, USA.
Lorraine C DrapekDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Lawrence S BlaszkowskyDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Bruce J GiantonioDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Colin D WeekesDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Andrew X ZhuDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Lipika GoyalDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Ryan D NippDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Jon S DuboisDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Emily E Van SeventerMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Bronwen E ForemanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Lauren E MatlackMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Leilana LyMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Jessica A MeurerDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Nir HacohenMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2349-2656
David P RyanDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Beow Y YeapDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Ryan B CorcoranDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA.
Benjamin D GreenbaumMemorial Sloan Kettering Cancer Center, New York, NY, USA.
David T TingDepartment of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA, USA. dting1@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-3261-2322
Theodore S HongDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. tshong1@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-8481-6581
Harvard University · USBroad Institute · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2M
Training Program in Cancer Biology and TherapeuticsT32CA071345 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber, Lecia V. Sequist · 1997 to 2026
$10.6M
Understanding the Relationship of Repeat Expression and MetastasisR01CA240924 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GREENBAUM, BENJAMIN, TING, DAVID TSAI · 2019 to 2023
$3.3M
A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor ImmunityU01CA228963 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GREENBAUM, BENJAMIN, TING, DAVID TSAI · 2020 to 2024
$3.2M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA240924NCI NIH HHS T32 CA071345NCI NIH HHS U01 CA228963
6 · The paper itself

Abstract

Overcoming intrinsic resistance to immune checkpoint blockade for microsatellite stable (MSS) colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) remains challenging. We conducted a single-arm, non-randomized, phase II trial (NCT03104439) combining radiation, ipilimumab and nivolumab to treat patients with metastatic MSS CRC (n = 40) and PDAC (n = 25) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The primary endpoint was disease control rate (DCR) by intention to treat. DCRs were 25% for CRC (ten of 40; 95% confidence interval (CI), 13-41%) and 20% for PDAC (five of 25; 95% CI, 7-41%). In the per-protocol analysis, defined as receipt of radiation, DCR was 37% (ten of 27; 95% CI, 19-58%) in CRC and 29% (five of 17; 95% CI, 10-56%) in PDAC. Pretreatment biopsies revealed low tumor mutational burden for all samples but higher numbers of natural killer (NK) cells and expression of the HERVK repeat RNA in patients with disease control. This study provides proof of concept of combining radiation with immune checkpoint blockade in immunotherapy-resistant cancers.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalColorectal NeoplasmsPancreatic NeoplasmsHumansImmune Checkpoint InhibitorsImmunologic FactorsImmunotherapyMicrosatellite RepeatsRadiotherapyTreatment OutcomeImmune Checkpoint InhibitorsImmunologic Factors

Identifiers

PMID35122060
PMCPMC8809884
OpenAlexW3214048256

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.